Analysed KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) News Sources
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
20-04-2026
yahoo.com
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
21-04-2026
yahoo.com
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
25-04-2026
marketbeat.com
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
04-05-2026
yahoo.com
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
12-05-2026
yahoo.com
KYV-101 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
15-05-2026
yahoo.com
What is the current price of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)?
The current price of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) is $7.82.
KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) since the previous trading day is $-0.08.
KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) since the previous trading day is -1.0127%.
What is the most recent average sentiment score for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)?
The most recent average sentiment score for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)?
The most recent sentiment for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) is .
SEC-8K** Filing Available For KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.